print program

Schedule

All satellites are open sessions and all registered conference attendees are welcome to attend.

 

Monday, 7 October

Room #

Time

Session Title

Room 122 08:30 - 10:30

Catalyzing a Health Innovation System that Works for All
Host Institution: Salud por Derecho – Right to Health Foundation
(Session Overview)

 

Room 124 08:30 - 10:30

Supporting HIV Vaccine R&D Using the CHVI R&D Alliance Virtual Community
Host Institutions: CHVI – Alliance Coordinating Office (ACO)
(Session Overview)

 

Room 123 08:30 - 11:30

Antibody and NK Recognition of HIV-1 Infected Cells
Host Institution: Duke University Medical Center
(Session Overview)

 

Room 130 09:00 - 10:30

Speaking Science to the Public
Host Institutions: AVAC, Global HIV Vaccine Enterprise
(Session Overview)

 

Room 129 10:30 - 13:30

Major Bottlenecks in HIV Vaccine Development: The Light at the End of the Tunnel
Host Institutions: European Commission + Universite Pierre et Marie Curie (FR)
(Session Overview) 

 

Room 130 11:00 - 12:15

Capturing Participant Information for Mucosal Sampling: an Investigator's Guide
Host Institutions: Global HIV Vaccine Enterprise, NIAID, the HIV Mucosal Immunology Group
(Session Overview)

 

Room 123 12:00 - 15:00

Structure and Antigenicity of Soluble, Cleaved (SOSIP) HIV-1 gp140 Trimers
Host Institutions: Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID)
(Session Overview) 

 

Room 130 12:30 - 13:30

From Bench to Clinic: A Researchers Guide to Move Vaccine Candidates into Trials
Host Institutions: IAVI, UK HIV Vaccine Consortium, Global HIV Vaccine Enterprise
(Session Overview)

 

Room 124 13:30 - 15:30

Enabling Technologies and Methods for HIV Vaccine Research and Clinical Trials
Host Institution: Fraunhofer Institute for Biomedical Engineering FhG IBMT, UniversitatPompeuFabra
(Session Overview) 

 

Room 127+
128
13:30 - 15:30

AIDS Vaccine Research at the Crossroads: How to Adapt to a New Prevention Agenda
Host Institution: International AIDS Vaccine Initiative
(Session Overview)

 

Room 130 14:00 - 15:00

Strategic Directions for Therapeutic HIV Vaccine Research
Host Institution: AVAC, TAG, Bill & Melinda Gates Foundation, Global HIV Vaccine Enterprise
(Session Overview) 

 

L1, Room 113 - 116
Speakers: Enric Banda, Boi Ruiz i Garcia, William Snow, Ntando Yola, Stanley A. Plotkin, Magdalena Sobieszczyk, Anthony Fauci

16:00 – 18:00

Opening Session

L1, Room 113 - 116

 

Chairs: Christian Brander, Bonaventura Clotet, and José Gatell

 

 

16:00 – 16:10

Welcome Remarks

2013 Conference Chairs

Christian Brander, IrsiCaixa Inst for AIDS Res, HIVACAT, ICREA, Barcelona, Spain

Bonaventura Clotet, IrsiCaixa Inst for AIDS Res, HIVACAT, Barcelona, Spain

José M. Gatell, Hospital Clínic, IDIBAPS, HIVACAT, University of Barcelona, Spain

 

 

16:10 – 16:20

Enric Banda
Director of the Area of Science, Research and the Environment, ”la Caixa” Foundation

 

16:20 – 16:30

Boi Ruiz i Garcia
Minister of Health, Government of Catalonia

 

16:30 – 16:40

Opening Remarks from the Vaccine Enterprise

William Snow
Global HIV Vaccine Enterprise, USA

 

 

16:40 - 16:50

Partnership Towards a Tough Target: Communities Are an Essential Ingredient, Not a Cherry on Top

Ntando Yola
NACOSA, Cape Town, South Africa

 

OS.01

16:50 - 17:13

HIV Vaccines in the Context of Vaccine Development in General

Stanley A. Plotkin
Univ of Pennsylvania, Doylestown, PA, USA

 

OS.02

17:13 - 17:36

Insights from HIV Vaccine Efficacy Trials: What We Are Learning from HVTN 505

Magdalena Sobieszczyk
Columbia Univ, New York, NY, USA

 

OS.03

17:36 - 18:00

Toward Ending the HIV/AIDS Pandemic: Synergy Between Vaccine and Non-vaccine Interventions

Anthony Fauci
NIAID, NIH, Bethesda, MD, USA

OS.04

 

 

 

L2, Banquet Hall
Rooms 117: L1
Oral Abstract Session 6
L1, 111 - 112, L2, 211 - 212
L1, Room 113 - 114
Symposium 1
Speakers: Marcus Altfeld, Alison Mahan, Daniel Zak, Bali Pulendran
L1, Room 115 - 116
Symposium 2
Speakers: David Masopust, Elias Haddad, Giuseppe Pantaleo, Shiv Pillai
L1, Room 117
Symposium 3
Speakers: David Watkins, Genoveffa Franchini, Louis Picker, Robin Shattock, Ronald Desrosiers
Rooms 113/114: L1
Rooms 115/116: L1
L1, Room 113 - 116
Speakers: Michael Pensiero, Andrew McMichael, Barton Haynes

08:30 - 09:00

Manufacturing HIV Envelope Proteins for HIV Vaccines: An NIAID Perspective of Where We Are and What Is Still Needed

Nicole Bernard
McGill University, Canada

 

PL01.01

09:00 - 09:30

Vaccine Induction of T Cell Immunity to HIV-1

Andrew McMichael
Univ of Oxford, Oxford, UK

 

PL01.02

09:30 - 10:00

Pathways of Affinity Maturation of HIV-1 Broadly Neutralizing Antibodies

Barton Haynes
Duke Human Vaccine Inst, Durham, NC, USA

 

PL01.03

Rooms 117: L1
L1, 111 - 112 | L2, 211 - 212
Rooms 111/112: L1 + Rooms 211/212: L2

Odd-numbered poster presentations will be presented in Poster Session 01.

Poster presentations are scheduled by topic and the last two digits of the abstract presentation number. For example, 1.01 is an odd-numbered abstract; whereas 1.02 is an even numbered abstract.

Poster Topics Presented in L1, Room 111 – 112

  • Adjuvants, Immunogens and Inserts
  • Animal Models and Preclinical Trials
  • B Cell Immunology and Antibody Functions
  • Clinical Vaccine Trials and Trial Site Challenges
  • HIV Transmission and Viral Diversity

Poster Topics Presented in L2, Room 211 – 212

  • Immunogenetic Factors
  • Innate Immunity
  • Mucosal Immunity
  • Non-Vaccine Prevention
  • Pediatric and Adolescent Infections and Trials
  • Social/Ethical/Access/Regulatory Issues
  • T Cell Immunity
  • Vaccine Concepts and Design
L1, Room 113 - 114
Oral Abstract Session 1
L1, Room 115 - 116
Oral Abstract Session 2
L1, Room 117
Oral Abstract Session 3
Exhibition Area: L0
L1, Room 113-114
Oral Abstract Session 4
Rooms 115/116: L1
Oral Abstract Session 5
Exhibition Area: L0
Rooms 113/114: L1
Symposium 5
Speakers: A. Haase, J. Martinez-Picado, E. Arts, T. Allen
Rooms 115/116: L1
Symposium 6
Speakers: J. Binley, J. Mascola, W. Schief, L. Stamatatos
Rooms 117: L1
Roundtable Discussion
Speakers: G. Gray, S. Hammer, P. Pitisuttithum, S. Buchbinder

 

Susan Buchbinder

San Francisco Department of Public Health, San Francisco, CA, USA

 

Glenda Gray

Perinatal HIV Research Unit, Johannesburg, South Africa

 

Scott Hammer

Columbia University Medical Center, NY, USA

 

Punnee Pitisuttithum

Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

 

 

L1, 111 - 112, L2, 211 - 212
Rooms 113/114: L1
Symposium 7
Speakers: JP. Routy, M. Stevenson, R. Geleziunas, M. Lederman
Rooms 115/116: L1
Symposium 8
Speakers: J. Mullins,C. Brander, M. McCune, M. Roederer
Rooms 117: L1
Symposium 9
Speakers: T. Murooka, J.V. Garcia, T. Hope, H. Shin
Poster Discussions Rooms 113/114: L1
L1, Room 113 - 116
Speakers: Rupert Kaul, Philip Goulder, Penny Moore

08:30 - 09:00

Genital Immunology and HIV Susceptibility

Rupert Kaul1

1Univ of Toronto, Ontario, Canada

 

PL02.01

09:00 - 09:30

Immunodeficiency Virus and the MHC: Past, Present and Future

Philip Goulder1

1Univ of Oxford, Oxford, UK

 

PL02.02

09:30 - 10:00

The Role of HIV-1 Viral Evolution in Shaping Broadly Neutralizing Antibodies

Penelope Moore1

1Nat'l Inst for Communicable Diseases, Johannesburg, South Africa

 

PL02.03

Rooms 115/116: L1
Rooms 117: L1
L1, 111 - 112 | L2, 211 - 212
Rooms 111/112: L1 + Rooms 211/212: L2

Even-numbered poster presentations will be presented in Poster Session 02.

Poster presentations are scheduled by topic and the last two digits of the abstract presentation number. For example, 1.01 is an odd-numbered abstract; whereas 1.02 is an even numbered abstract.

Poster Topics Presented in L1, Room 111 – 112

  • Adjuvants, Immunogens and Inserts
  • Animal Models and Preclinical Trials
  • B Cell Immunology and Antibody Functions
  • Clinical Vaccine Trials and Trial Site Challenges
  • HIV Transmission and Viral Diversity

Poster Topics Presented in L2, Room 211 – 212

  • Immunogenetic Factors
  • Innate Immunity
  • Mucosal Immunity
  • Non-Vaccine Prevention
  • Pediatric and Adolescent Infections and Trials
  • Social/Ethical/Access/Regulatory Issues
  • T Cell Immunity
  • Vaccine Concepts and Design
L1, Room 113 - 114
Oral Abstract Session 7
Rooms 115/116: L1
Oral Abstract 8
L1, Room 117
Symposium 4
Speakers: G. Voss, T. Matano, A. Geall, H. Robinson
Rooms 113 - 116: L1

13:00 – 13:20

What Has 30 Years of HIV Vaccine Research Taught Us? Lessons from The Past To Inform The Future

José Esparza1

1Bill & Melinda Gates Foundation, Seattle, WA, USA

CS.01

13:20 – 13:25

AIDS Vaccine 2013 At-A-Glance
2013 Conference Chairs

Christian Brander1Bonaventura Clotet2José M. Gatell3

1IrsiCaixa Foundation, HIVACAT, ICREA, Barcelona, Spain; 
2IrsiCaixa Foundation, HIVACAT, Barcelona, Spain; 
3Hospital Clínic-IDIBAPS, University of Barcelona, HIVACAT, Spain 

CS.02 

13:25 – 13:35

AIDS Vaccine Research, Where We Are and Where We Are Going

Nina Russell1,2

1Bill & Melinda Gates Foundation, Seattle, WA, USA,
2Global HIV Vaccine Enterprise, New York, NY, USA

 CS.03

13:35 – 13:50

HIV Research for Prevention
2014 Conference Co-Chairs

Eric Hunter1, Robin Shattock2

1Emory Univ, Atlanta, GA, USA,
2Imperial College London, UK

CS.04 

Lunch on own
Room 124+
125
15:00 - 17:00 Meta-Analysis of HVTN Efficacy Studies with Adenovirus Vectors
Host Institution: Fred Hutchinson Cancer Research Center and the HIV Vaccine Trials Network
(Session Overview)
L1, Room 113 - 116
Speakers: María José Alonso, Behazine Combadiere, Adrian Hill

08:30 - 09:00

Nanotechnology Approaches for Designing Novel HIV Vaccines

M. Luo1, Maria Jose Alonso2

1Univ of Manitoba, Manitoba, Canada;
2Univ of Santiago de Compostela, Santiago de Compostela, Spain

 

PL03.01

09:00 - 09:30

Cutaneous Routes for HIV Vaccination Strategies

Behazine Combadiere1

1INSERM, UPMC, Paris, France

 

PL03.02

09:30 - 10:00

HIV Vaccine Development: A View from the Outside

Adrian Hill1

1Univ of Oxford, Oxford, UK

 

PL03.03

L1, Room 113 - 116
Plenary 4
Speakers: Tomas Hanke, Muhammad Bakari, Robert O'Connell, Georgia Tomaras, Glenda Gray, Peter Gilbert

10:30 - 10:55

The First Clinical Evaluation of Conserve-Region Vaccines in Humans

P. Hayes1, J. Vasilyeva2, N. Frahm2, J. Cox1, S. Colloca3, A. Nicosia4, J. Gilmour1, Tomas Hanke5

1IAVI, Imperial College, London, UK; 2FHCRC, Seattle, WA, USA; 3Okairos, Rome, Italy; 4Okairos, CEINGE, Univ of Naples, Naples, Italy; 5Univ of Oxford, Oxford, UK

 

PL04.01

10:55 - 11:20

The HIVIS and TaMoVac Studies, a North-South Collaboration

Muhammad Bakari1

1Muhimbili Univ of Hlth and Allied Sciences, Dar es Salaam, United Republic of Tanzania

 

PL04.02

11:20 - 11:45

Looking Back to Move Forward: Understanding ALVAC/AIDSVAX Immune Responses

Merlin Robb1

1AFRIMS, Bangkok, Thailand

 

PL04.03

11:45 - 12:10

Vaccine Induced Antibody Responses in HVTN 505, a Phase IIb HIV-1 Efficacy Trial

Georgia Tomaras1

1Duke Univ, Durham, NC, USA

 

PL04.04

12:10 - 12:35

An Update on the Phambili/HVTN 503 Study, a Phase IIB HIV Vaccine Efficacy Study Investigating MRK Ad5 HIV-1 Subtype B gag/pol/nef Vaccine

Glenda Gray1

1Perinatal HIV Res Unit, Johannesburg, South Africa

 

PL04.05

12:33 - 13:00

Meta-Analysis of Ad5-vector HIV Vaccine Trials to Assess the Vaccine Effect on HIV Acquisition

Y. Huang1, D. Follmann2, M. Nason2, L. Zhang1, Y. Huang1, D. Mehrotra3, Z. Moodie1,

B. Metch1, H. Janes1, M. Keefer4, G. Churchyard6, M. Robb10, P. Fast5, A. Duerr1, L. Corey1,

J. Mascola2, B. Graham2, M. Sobieszczyk7, J. Kublin1, M. Robertson3, S. Hammer7, G. Gray8,

S. Buchbinder9, Peter Gilbert1

1FHCRC, Seattle, WA, USA; 2NIAID, Bethesda, MD, USA; 3Merck, USA; 4Univ of Rochester Med Center,

Rochester, NY, USA; 5International AIDS Vaccine Initiative (IAVI); 6Aurum Institute, Johannesburg, South Africa;

7Columbia Univ, New York, NY, USA; 8Perinatal HIV Research Unit, South Africa; 9San Francisco Dept of Publ Hlth,

San Francisco, CA, USA; 10U.S. Military HIV Research Program, Bethesda, MD, USA

 

PL04.06